Visiongain Publishes Cardiac Safety Services Market Report 2021-2031

29 October 2020

Visiongain has published a new report on Cardiac Safety Services Market : Forecasts by Type (Standalone, Integrated), Services (ECG/Holter Measurement, Blood Pressure, Cardiac Imaging, Thorough QT Study, Other Services), End User (Pharmaceutical & Biopharmaceutical Companies, CRO). PLUS Profiles of Leading Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.

Global Cardiac Safety Services market was valued at US$ xx billion in 2020 and is projected to reach at a market value of US$ xx billion by 2031.

Global Cardiac services is likely to grow by the factors such as growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increased outsourcing of R&D activities, and increasing number of clinical trials, the introduction of new technology and methods and growth in the biosimilars and biologics market are expected to provide a wide range of growth.

COVID-19 Impact on Cardiac Safety Services
After this life taking pandemic COViD-19, awareness related to cardiovascular disease is getting wide-spread among the masses owing to the panic and fear created by the virus spread. Thus, this market is likely to grow in future period.

Segment Analysis
- The global market for cardiac safety services is categorised on the basis of service type, the market is further classified into blood pressure measurement services, cardiovascular imaging services, ECG measurement services, thorough QT studies.
- Based on end user, the market is segmented into pharmaceutical & biopharmaceutical companies and contract research organizations (CROs). The pharmaceutical & biopharmaceutical companies segment recorded for the largest market share in 2019. This segment is also predicted to be growing at the fastest rate during the analysis period. The large share of this segment is contributed by the factors such as the stringent regulations for drug safety and increasing R&D activities to develop new drugs.
- The Contract research organisation segment is projected to have a substantial growth in the market due to the upsurge in the number of contract research services across the world.

Market Drivers
- Cardiac Safety Services market growth is largely attributed to the aspects such as the growing R&D spending in the pharmaceutical & biopharmaceutical industry, increased subcontracting of R&D activities, and the increasing number of clinical trials.
- Moreover, the invention of new technologies & methods and growth in the biosimilars and biologics market are expected to provide a wide range of growth opportunities for players operating in this market.

Market Opportunities
- Increase in patients having cardiovascular diseases and awareness in the health relating problems. People are on the way to take right treatment which is proving to be a growth opportunity for the Cardiac Safety Services Market to grow.

Competitive Landscape
Global Cardiac safety services market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships,acquisitions and others to increase their footprints in this market. Some of the companies mentioned are-Biotrial(France), Banook Group(France and Canada),Bioclinica(subsidiary of Cinven (US)),Centera LP(US), Celerion Inc.(US),ERT Inc. (US), Laboratory Corporation of America Holdings(US),Medpace Holdings Inc. (US),NcardiaAG(Belgium), RichmondPharmacology (UK), Phsiostim (France),Shanghai Medicilon Inc. (China), Pharmaceutical Product Development LLC. (US), SGS S.A(Switzerland),BioTelemetry, Inc. (US),IQVIA (US).

Recent Developments
• In 2018, ERT introduced its rapid ECG.
• In 2018, Bioclinica introduced an expanded and improved 'SMART' technology suite available with medical imaging, EDC, and IRT.
• In 2018, ERT launched its Phase I QT Centre of Excellence in France

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes ePharmacy Market Report 2021-2031

The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.

06 May 2021


Visiongain Publishes Protein Labelling Reagents for Research Use Only (RUO) Market Report 2021-2031

Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.

05 May 2021


Visiongain Publishes Aptamer Technologies Market Report 2021-2031

Over the last few years, the aptamers has gained widespread attention due to the technological advancements and growth in understanding of the oligonucleotide therapeutics that inhabit the human body.

29 April 2021


Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031

Rising prevalence of inflammatory bowel disease including Crohn’s disease and ulcerative colitis; raising awareness for IBD in developing countries; escalating investment in drug R&D by pharmaceutical companies; new product launches worldwide, growing chronic diseases healthcare awareness are some of the major factors that boosting the growth of global IBD drugs market.

29 April 2021